Investigational Drug Details
| Drug ID: | D281 |
| Drug Name: | Bromfenac |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB00963 |
| DrugBank Description: | Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool to optimize surgical outcomes. |
| PubChem ID: | 60726 |
| CasNo: | 91714-94-2 |
| Repositioning for NAFLD: | Yes |
| SMILES: | NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 |
| Structure: |
|
| InChiKey: | ZBPLOVFIXSTCRZ-UHFFFAOYSA-N |
| Molecular Weight: | 334.165 |
| DrugBank Targets: | Prostaglandin G/H synthase 2; Prostaglandin G/H synthase 1 |
| DrugBank MoA: | The mechanism of its action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase 1 and 2. Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure. |
| DrugBank Pharmacology: | Bromfenac ophthalmic solution is a sterile, topical, nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. |
| DrugBank Indication: | For the treatment of postoperative inflammation in patients who have undergone cataract extraction. |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|